Anti-Eribulin payload antibody in PK study in ADC drug development

Anti-eribulin antibodies are employed in PK studies to assess the concentration of eribulin and its conjugates in biological matrices with high accuracy. Eribulin mesylate is a synthetic version of the natural product – Halichondrin B derived from Halichondria okadai sponge; it is primarily used for the treatment of metastatic breast cancer and liposarcoma. Similar to camptothecin, eribulin can further be used in ADCs as a payload to an antibody that targets cancer cells.

**Product list of GeneMedi's anti-Eribulin antibody**
Cat No.	Product Description	Fc	Products Information
GTU-Bios-Eribulin-Ab	Anti-Eribulin-monoclonal-antibody (mAb)	hFc/mFc	Details

All Payloads of ADCs

Application

Competitive immunoassay validation (CompetitiveELISA) and other Immunoassay,
PK & PD assay for MMAE payload of Antibody-drug Conjugate (ADC)

Highlight:

Purity: ≥95% (SDS-PAGE)
High affinityand specificity validated
High sensitivity verified by ADCs binding assay

Application
Technical Resource

Why Use Anti-Eribulin Antibody in ADC drug development?

1. Specificity: Anti-eribulin antibodies are molecules, which are created to react selectively with eribulin and its congeners. This specificity is essential for the identification of pharmacokinetic parameters for the whole drug and more so if it is part of an ADC. This allows for each of the free drug as well as the ADC to be analyzed by AUC separately due to precise measurement.
2. Sensitivity: These antibodies are useful for the detection of trace amounts of eribulin, which is necessary for the determination of the therapeutic and toxic concentration of the drug within the body, due to its highly potent and intensive cytotoxic effect.
3. Efficacy and Safety Evaluation: Understanding the pharmacokinetic profile, particularly when conjugated to an ADC, is beneficial when determining the ability of the drug to home in on the tumor target cells and the rate at which the loading agent releases the payload within the tumor milieu. This assessment is paramount in establishing is the treatment method correct and whether the client is safe or not.

How to use Anti-Eribulin Antibody in ADC drug development?

Development of Immunoassays: Anti-eribulin antibodies are employed to prepare different immunoassay as described above like ELISA this assays can be utilized to determine the concentration of eribulin in plasma, serum and any other tissue. These assays assist in ascertaining the biodisposition and clearance rates of the concerned drug.
Sample Collection and Analysis: In a PK study, blood or any other biological fluids are sampled on fixed time after giving the drug. These samples are then analyzed using immunoassays that incorporate anti-eribulin antibodies through the use of Eri-Ab as developed by own. It aids in calculating the surviving concentration of eribulin at a certain time, information that is useful in understanding the drug’s pharmacokinetic profile including its absorption, distribution, metabolism, and excretion.
Data Utilization: The data acquired from PK studies assist in establishing the kinetic behavior of eribulin and selecting the right dosing regimens. It is also critical when it comes to studying the drug’s compatibility with biological systems, estimating likely negative reactions, as well as the chance of achieving the best therapeutic outcomes.

PK studies of ADCs and application of anti-eribulin antibodies as well as stand-alone treatments require eribulin for proper development of new treatment options. It fades knowledge gaps that would otherwise expose cancer patients under therapeutic development to ineffective and dangerous drugs because of inaccurate pharmacokinetic data.